# Impact of NOS, COX, and ROS Inhibition on Cerebral Blood Flow Regulation

> **NCT03066115** · PHASE1 · WITHDRAWN · sponsor: **University of Wisconsin, Madison**

## Conditions studied

- Hypoxia
- Hypercapnia

## Interventions

- **DRUG:** L-NMMA
- **DRUG:** Ketorolac
- **DRUG:** Ascorbic Acid
- **PROCEDURE:** Intravenous Catheter
- **PROCEDURE:** Transcranial Doppler Ultrasound

## Key facts

- **NCT ID:** NCT03066115
- **Lead sponsor:** University of Wisconsin, Madison
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-12-01
- **Primary completion:** 2021-12-01
- **Final completion:** 2021-12-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** This study was never funded, never fully IRB approved, and thus never enrolled anyone.
- **Last updated:** 2019-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03066115

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03066115, "Impact of NOS, COX, and ROS Inhibition on Cerebral Blood Flow Regulation". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03066115. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*